Plain-English translation of ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested whether combining and could effectively treat advanced kidney cancer in two groups of patients: those with a hereditary form called HLRCC and those with a sporadic form called papillary renal cell cancer. Both medications work by blocking different pathways that help cancer cells grow and spread. The trial investigated whether using them together would be more effective than either one alone.
These two types of kidney cancer are aggressive and difficult to treat, and researchers believed that blocking multiple growth pathways at once might work better than existing treatments. The specific genetic changes in HLRCC suggested that this particular combination might be especially helpful.
Participants received as an intravenous infusion every two weeks and as a daily pill by mouth. The trial monitored how well the cancer responded to this combination and tracked any side effects through regular medical visits and imaging scans. Participants needed to provide a tissue sample from their tumor for research purposes and undergo blood tests to ensure their organs were handling the medications safely.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States